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Summary
Since it emerged in China in the late 2019, the SARS-CoV-2 virus has spread throughout the world and caused the 
newest pandemic. The epidemiological characteristics of the virus and the clinical manifestations of the COVID-19 
disease are currently being studied. The new data is emerging continuously but not yet fully understood. So far, we 
have learned a lot about the virus and the disease but more research is needed as many issues are still being explored.
Sažetak
Otkako se pojavio u Kini krajem 2019. godine, virus SARS-CoV-2 proširio se cijelim svijetom i izazvao najnoviju 
pandemiju. Epidemiološke značajke virusa kao i kliničke manifestacije bolesti COVID-19 su još uvijek predmet 
istraživanja. Neprestano dolazimo do novih spoznaja, ali još uvijek ne razumijemo u potpunosti SARS-CoV-2 virus 
i bolest koju uzrokuje. Do sada smo velikom brzinom naučili dosta o virusu i COVID-19 bolesti, ali je potrebno još 
više istraživanja, jer su mnoga pitanja još uvijek otvorena.
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Brief History of COVID-19 Pandemic 
 The first reports of a new respiratory disease ac-
companied by pneumonia appeared in December 2019 
in the city of Wuhan in the province of Hubei in Chi-
na. Since the first reports of cases from Wuhan, more 
than 82,000 coronavirus disease 2019 (COVID-19) 
cases have been reported in China so far, culminat-
ing in March 2020.[1] The World Health Organisation 
declared COVID-19 pandemic on March 11, 2020.[2] 
Until now, cases have been reported on all continents 
except Antarctica, with a total number rising to more 
than 6 million cases worldwide by June 1, 2020.[1] The 
first confirmed and laboratory-proven case in Croatia 
was a young man from Zagreb, who arrived on Febru-
ary 20, 2020 from the Italian province of Lombardy, 
which has been officially affected by the new Corona-
virus epidemic since February 21, 2020.[3]
About the Virus
 In late December 2019 in Wuhan, China, a new 
beta-Coronavirus was confirmed in patients with 
unknown respiratory viral disease and pneumonia. 
Meanwhile, the genome sequencing of the Severe 
Acute Respiratory Syndrome 2 (SARS-CoV-2) virus 
from a person with COVID-19 showed it is sharing 
79.5% of the sequence with SARS-CoV, while 93.3% 
of its genome is identical to the newly identified bat 
Coronavirus from bats living in the Yunnan Province 
of southern China. This virus also appears to contain 
insertions of amino acids in two subunits, S1 and S2, 
of the virus's spike protein, the feature found in SARS-
CoV-2, leading to the theory of the zoonotic origin of 
the virus.[4]
 Another similar bat coronavirus, known since 
2013, shares 96.1% of its genome with SARS-CoV-2.
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a report of a screening program of pregnant women 
presenting for delivery at two New York hospitals dur-
ing the pandemic, 29 of 210 asymptomatic women 
(14%) were positive for a SARS-CoV-2 RT-PCR test.
[13] Nishiura H. and colleagues estimated the ratio of 
asymptomatic individuals, using the information on 
Japanese evacuated by charter flights from Wuhan to 
China, is 30.8%.[14] Transmission of SARS-CoV-2 from 
asymptomatic subjects (or from subjects within the 
incubation period) has been described. In an analy-
sis of 157 cases of locally acquired COVID-19 cases 
in Singapore, estimated is that the transfer during the 
incubation period is 6.4%; in such cases, exposures oc-
curred one to three days prior to the symptoms onset.
[15] However, the extent to which this occurs remains 
unknown.
 There have been reports of SARS-CoV-2 asympto-
matic infection with radiological abnormalities. One 
such report of 55 patients with asymptomatic infection 
identified through contact tracing showed that 67% 




 The incubation period is reported to be 3 to 14 days. 
In a study of 1,099 patients with confirmed sympto-
matic COVID-19 disease, the mean incubation period 
was 4 days (interquartile range 2 to 7 days).[17] Accord-
ing to one estimate, as many as 97.5% of individuals 
developed fever up to 12.5 days from exposure.[15]
 A 3-stage classification of COVID-19 disease based 
on severity has been proposed: Stage I (mild) – early 
infection, Stage II (moderate) - pulmonary involve-
ment (IIa) without and (IIb) with hypoxia and Stage 
III (severe) – systemic hyperinflammation, correspond 
with distinct clinical finding, response to therapy and 
clinical outcome.[18]
 Evaluation and management of COVID-19 de-
pends on the disease severity. According to a report of 
72,314 cases from China, the course of COVID-19 dis-
ease varies from mild (81% of cases) to moderate, re-
quiring hospitalization and monitoring (14% of cases), 
to severe, requiring intensive treatment (5% of cases).
[19] Mild disease is usually self-limiting with symptoms 
resolution within two weeks.[19] Patients with moder-
ate or severe COVID-19 are usually hospitalized for 
observation and supportive care.
 To our knowledge, there are no specific clinical 
features that distinguish COVID-19 from other viral 
respiratory infections. The largest report from China 
described the most common symptoms, which were: 
[5] The SARS-CoV-2 has been shown to have the same 
cell entry receptor, ACE2, as SARS-CoV.[5] Neither of 
the viruses is a direct ancestor of SARS-CoV-2.
 A report of autopsy tissue samples, obtained from 
22 patients who had died from COVID-19 reviewing 
SARS-CoV-2 viral load, detected the highest levels of 
SARS-CoV-2 copies per cell in the respiratory tract. 
Furthermore, the virus has been detected in the kid-
neys, liver, heart, brain, and blood, although in lower 
viral loads.[6]
Transmission Mode
 The complete understanding of the SARS-CoV-2 
transmission pathway is still unsolved. An epidemio-
logical investigation in Wuhan at the beginning of the 
epidemic identified a possible link to the seafood mar-
ket selling live animals.[1] However, as the epidemic 
progressed, human-to-human spread became the main 
transmission mode. It is believed that SARS-CoV-2 
is spread by droplets, including coughing, sneezing, 
and talking, but also by direct mucosal contact with 
the infected person; infection can occur indirectly via 
contact with an infected surface. The droplets usually 
do not travel more than six meters and do not remain 
in the air.[7] Although one study showed SARS-CoV-2 
can remain viable in experimentally produced aerosols 
for at least three hours, its relevance to the epidemiol-
ogy of COVID-19 and its clinical implications are not 
clear.[8] RNA SARS-CoV-2 was detected in blood and 
stool samples, but the fecal-oral transmission does not 
appear to be a significant factor in the infection spread.
[9] The interval, during which an individual with COV-
ID-19 is contagious, has not yet been fully elucidat-
ed. Most data originate from the studies assessing the 
presence of viral RNA in respiratory and other sam-
ples, with positivity persisting on average of 44.9 days 
(range 8 – 82 days) after the initial occurrence of the 
symptoms.[10]
 However, the presence of viral RNA does not nec-
essarily indicate the ability to infect. Viral RNA levels 
in the upper airway samples appear to be higher after 
the onset of symptoms, compared to the later stage of 
the disease.[11] An important factor enabling the virus 
spread is the transmission by asymptomatic persons. 
In one report from a nursing facility in the USA, more 
than half (27 of 48) of the residents who were asymp-
tomatic at testing, had positive tests for SARS-CoV, 
with 24 of those becoming symptomatic in the follow-
ing week, thus contributing to the virus spread.[12]
Asymptomatic Infections
 Asymptomatic infections seem to be common but 
their precise frequency remains to be determined. In 
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the symptoms onset; 12.3% of patients were on me-
chanical ventilation.[21, 26] Similar trend was described 
in studies in the USA (14.2% hospitalized patients 
required treatment in ICU, 12.2% mechanical ventila-
tion, while 3.2% were treated with hemodialysis).[20]
 A group of researchers described postmortem 
findings from 10 consecutive patients with confirmed 
COVID-19 as showing acute and organizing diffuse 
alveolar damage as the primary histopathologic find-
ing and the leading cause of death among patients, re-
gardless of treatment with invasive ventilation.[28] Age 
over 65 years, diabetes, and arterial hypertension were 
more common in patients with ARDS.[27]
 Other common complications of COVID-19 in-
clude respiratory failure, sepsis, acute myocardial inju-
ry, defined by elevated troponin levels, cardiac decom-
pensation, renal failure, and hypoxic encephalopathy. 
These complications were more common in patients 
with comorbidities, but even after adjustment for co-
morbidities, they increased the risk of death of COV-
ID-19 in previously healthy individuals.[29, 30, 31]
 The most common abnormal laboratory parameter 
is lymphopenia, followed by leukopenia and leuko-
cytosis. Elevated levels of LDH, ferritin, and AST are 
common. On admission, many patients with pneumo-
nia have normal serum procalcitonin levels; however, 
individuals requiring admission to the intensive care 
unit are more likely to have elevated procalcitonin.[26] 
High levels of D-dimer and more severe lymphopenia 
were present in patients with higher mortality.[32]
 Mehta and colleagues emphasized the growing ev-
idence suggesting a subgroup of patients with severe 
COVID-19 might have cytokine storm syndrome.[33] In 
a cohort from two New York hospitals, the researchers 
estimated inflammation of the 257 (22%) patients who 
required intensive care, finding a 10% increase in risk 
for death with every 10% increase of IL-6 or D-dim-
er concentration.[34] Additionally, high blood levels of 
cytokines and chemokines have been detected in pa-
tients with COVID-19, including: IL1-β, IL1RA, IL7, 
IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFNγ, IP10, 
MCP1, MIP1α, MIP1β, PDGFB, TNFα, and VEGFA.[35]
Hypercoagulability and Cardiovascular Manifestations
 COVID-19 has been associated with a hypercoag-
ulable state with an increased risk of venous thrombo-
embolism.[36] In one observational study, the authors 
compared the occurrence of thromboembolic events 
between non-COVID-19 ARDS and COVID-19 ARDS 
patients. They found clinically relevant thrombotic 
complications in 64 of 150 patients with COVID-19, 
most commonly pulmonary embolisms (16.7%). In 
comparison with 145 non-COVID-19 ARDS patients, 
fever (88.7%) and cough (67.8%), general weakness 
(38.1%), expectoration (33.7%), shortness of breath 
(18.7%), myalgia and arthralgia (14.9%), sore throat 
(13.9%), headache (13.6%) and chills (11.5%),[19] with 
similar symptoms reported in a study of 5700 patients 
in New York City Area, USA.[20] However, one study 
reported fever >38°C at a presentation in only half the 
patients,[21] while another one in only 31% of patients.
[20] Some cohorts reported around 40% of patients 
presenting with gastrointestinal symptoms such are 
anorexia, nausea, and diarrhoea, while up to 10% of 
patients present with gastrointestinal symptoms with-
out respiratory symptoms or fever.[22, 23] Lately, reports 
of smell and taste disorder emerged from Italy.[24] In 
one survey from Italy of 202 outpatient adults who 
were diagnosed with mild disease, the alteration of 
the sense of smell or taste was reported by 64.4% of 
the patients. Another Italian study described the oc-
currence of anosmia and ageusia before the onset of 
typical COVID-19 symptoms in 11.9% of the patients; 
in 3.0% of patients those were the only symptoms.[25]
The clinical condition of some patients who initially 
have mild symptoms may worsen within a week.[26] 
Based on several studies from China of the patients 
hospitalized in Wuhan for COVID-19 and pneumo-
nia, dyspnea occurred on average on the fifth day af-
ter the onset of symptoms, while the median from the 
onset of symptoms to hospitalization was 7 days.[15, 27]
Table 1. Risk factors for severe COVID-19[17, 19, 21, 26, 27, 43]
Tablica 1. Rizični faktori za teški oblik bolesti 
COVID-19[17,19,21,26,27,43]









Immunocompromised people (e.g. use of biologics, history of 
transplant or other immunosuppression, HIV)
Complications
 Acute respiratory distress syndrome (ARDS) is a 
major complication in patients with severe disease and 
may manifest soon after the development of dyspnea. 
In reports from China, ARDS developed in 20% of 
hospitalized patients in the interval of 8 – 12 days after 
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Around the same time, South Korea reported the esti-
mated case fatality rate of 0.9%[48], which may be due 
to demographics. A significant proportion of deaths in 
Italy is over 90 years of age, with an age-specific case 
fatality rate of 22.7%, compared with China, which 
does not stratify over 90 years of age.[36]
 In Italy, the mortality rate of patients admitted to 
intensive care units was 26%.[31] On the other hand, in 
a study of 2634 hospitalized patients from New York 
City, of 12% patients who received invasive mechani-
cal ventilation, 88% died.[20]
 In patients with comorbidities, the mortality rate 
is significantly higher - 10.5 % for cardiovascular dis-
eases, 7.3% for diabetes, 6.3% for chronic respiratory 
diseases, 6.0% for hypertension, and 5.6% for cancer[27] 
In one report from Italy, of 355 patients who died with 
COVID 19, the mean value of chronic diseases was 
2.7, while only three patients were previously healthy.
[47] These outcomes vary in affected countries, although 
a mild form of the disease predominates everywhere.
According to several studies concurrent with ACEI/
ARB, the therapy is not a risk factor for the develop-
ment of severe COVID-19 and does not increase the 
risk of death.[49, 50]
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